AU2017354041B2 - Alpha-V beta-6 integrin ligands and uses thereof - Google Patents

Alpha-V beta-6 integrin ligands and uses thereof Download PDF

Info

Publication number
AU2017354041B2
AU2017354041B2 AU2017354041A AU2017354041A AU2017354041B2 AU 2017354041 B2 AU2017354041 B2 AU 2017354041B2 AU 2017354041 A AU2017354041 A AU 2017354041A AU 2017354041 A AU2017354041 A AU 2017354041A AU 2017354041 B2 AU2017354041 B2 AU 2017354041B2
Authority
AU
Australia
Prior art keywords
amino acids
integrin
amino acid
art
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017354041A
Other languages
English (en)
Other versions
AU2017354041A1 (en
Inventor
Aaron ALMEIDA
Erik W. Bush
Jeffrey Carlson
Matthew FOWLER-WATTERS
Angieszka Glebocka
Zhen Li
Anthony Nicholas
Tao Pei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Pharmaceuticals Inc
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of AU2017354041A1 publication Critical patent/AU2017354041A1/en
Application granted granted Critical
Publication of AU2017354041B2 publication Critical patent/AU2017354041B2/en
Priority to AU2024202695A priority Critical patent/AU2024202695A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
AU2017354041A 2016-11-01 2017-11-01 Alpha-V beta-6 integrin ligands and uses thereof Active AU2017354041B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202695A AU2024202695A1 (en) 2016-11-01 2024-04-24 Alpha-v beta-6 integrin ligands and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415752P 2016-11-01 2016-11-01
US62/415,752 2016-11-01
PCT/US2017/059550 WO2018085415A1 (en) 2016-11-01 2017-11-01 Alpha-v beta-6 integrin ligands and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202695A Division AU2024202695A1 (en) 2016-11-01 2024-04-24 Alpha-v beta-6 integrin ligands and uses thereof

Publications (2)

Publication Number Publication Date
AU2017354041A1 AU2017354041A1 (en) 2019-04-11
AU2017354041B2 true AU2017354041B2 (en) 2024-02-01

Family

ID=62076333

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017354041A Active AU2017354041B2 (en) 2016-11-01 2017-11-01 Alpha-V beta-6 integrin ligands and uses thereof
AU2024202695A Pending AU2024202695A1 (en) 2016-11-01 2024-04-24 Alpha-v beta-6 integrin ligands and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202695A Pending AU2024202695A1 (en) 2016-11-01 2024-04-24 Alpha-v beta-6 integrin ligands and uses thereof

Country Status (20)

Country Link
US (2) US11180529B2 (enExample)
EP (2) EP3981780A1 (enExample)
JP (3) JP7291624B2 (enExample)
KR (1) KR102634762B1 (enExample)
CN (2) CN117285626A (enExample)
AU (2) AU2017354041B2 (enExample)
CA (1) CA3039618A1 (enExample)
DK (1) DK3535397T3 (enExample)
EA (1) EA201991102A1 (enExample)
ES (1) ES2906109T3 (enExample)
HR (1) HRP20220181T1 (enExample)
IL (2) IL266343B2 (enExample)
JO (1) JOP20190084B1 (enExample)
MX (3) MX2019004909A (enExample)
PL (1) PL3535397T3 (enExample)
SA (1) SA519401709B1 (enExample)
SI (1) SI3535397T1 (enExample)
TW (1) TWI776821B (enExample)
WO (1) WO2018085415A1 (enExample)
ZA (2) ZA201901905B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085415A1 (en) * 2016-11-01 2018-05-11 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
KR102605460B1 (ko) 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
CN110832077B (zh) 2017-07-06 2025-01-03 箭头药业股份有限公司 用于抑制α-ENaC表达的RNAi剂及使用方法
EP3843727A4 (en) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
TW202035400A (zh) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 抑制αvβ6整合素
KR102663798B1 (ko) 2019-06-25 2024-05-03 주식회사 엘지에너지솔루션 배터리 시스템
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
KR20230066400A (ko) * 2020-09-11 2023-05-15 애로우헤드 파마슈티컬스 인코포레이티드 인테그린 표적화 리간드 및 그의 용도
TW202227627A (zh) 2020-09-11 2022-07-16 美商愛羅海德製藥公司 用於抑制DUX4表現之RNAi藥劑、其組合物及使用方法
CA3189071A1 (en) * 2020-09-11 2022-03-17 Xiaokai Li Skeletal muscle delivery platforms and methods of use
IL301186A (en) * 2020-09-11 2023-05-01 Arrowhead Pharmaceuticals Inc Skeletal muscle delivery platforms and methods of use
JP2024516096A (ja) 2021-04-08 2024-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
KR20240014067A (ko) 2021-05-28 2024-01-31 애로우헤드 파마슈티컬스 인코포레이티드 뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
EP4547683A2 (en) 2022-06-30 2025-05-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000660A1 (de) * 1999-06-26 2001-01-04 Merck Patent Gmbh INHIBITOREN DES INTEGRINS αv$(g)b¿6?
WO2015160770A1 (en) * 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
DE10118550A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009069727A1 (ja) 2007-11-28 2009-06-04 Fujifilm Corporation 生体高分子およびポリペプチドの化学修飾方法
WO2012069655A2 (en) 2010-11-26 2012-05-31 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
WO2013123152A2 (en) * 2012-02-17 2013-08-22 Seattle Genetics, Inc. ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
WO2016164357A1 (en) 2015-04-06 2016-10-13 The Board Of Regents Of The University Of Oklahoma Phages for biomarker capture and methods of use
EP3130912B1 (de) 2015-08-14 2017-06-28 Sick Ag Verfahren zur bestimmung der konzentration einer gaskomponente und spektrometer dafür
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2018085415A1 (en) * 2016-11-01 2018-05-11 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000660A1 (de) * 1999-06-26 2001-01-04 Merck Patent Gmbh INHIBITOREN DES INTEGRINS αv$(g)b¿6?
WO2015160770A1 (en) * 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONIBEAR, A.C. et al., "Arginine side-chain modification that occurs during copper-catalysed azide-alkyne click reactions resembles an advanced glycation end product", June 2016. Org. Biomol. Chem., Vol.14, No.26, pgs.6205-6211. *
SHUNZI LI ET AL: "Synthesis and biological evaluation of a peptidepaclitaxel conjugate which targets the integrin", 2011. BIOORGANIC & MEDICINAL CHEMISTRY, Vol.19, No.18, pgs.5480-5489. *

Also Published As

Publication number Publication date
BR112019008965A2 (pt) 2019-07-09
US11180529B2 (en) 2021-11-23
ES2906109T3 (es) 2022-04-13
WO2018085415A1 (en) 2018-05-11
ZA201901905B (en) 2022-11-30
JP2025107348A (ja) 2025-07-17
SI3535397T1 (sl) 2022-04-29
JOP20190084A1 (ar) 2019-04-16
DK3535397T3 (da) 2022-01-31
IL305158A (en) 2023-10-01
SA519401709B1 (ar) 2023-06-04
MX2019004909A (es) 2019-08-12
MX2023007046A (es) 2023-06-23
AU2024202695A1 (en) 2024-05-16
JP7291624B2 (ja) 2023-06-15
IL266343B1 (en) 2023-09-01
CA3039618A1 (en) 2018-05-11
NZ751843A (en) 2025-05-02
US20220024975A1 (en) 2022-01-27
CN109952376A (zh) 2019-06-28
EP3981780A1 (en) 2022-04-13
US20190248832A1 (en) 2019-08-15
AU2017354041A1 (en) 2019-04-11
ZA202203240B (en) 2024-06-26
CN117285626A (zh) 2023-12-26
PL3535397T3 (pl) 2022-03-07
IL266343A (en) 2019-06-30
MX2023007051A (es) 2023-06-23
JOP20190084B1 (ar) 2023-09-17
KR102634762B1 (ko) 2024-02-06
EP3535397B1 (en) 2022-01-05
KR20190075937A (ko) 2019-07-01
TWI776821B (zh) 2022-09-11
EP3535397A1 (en) 2019-09-11
JP2019535685A (ja) 2019-12-12
US12173086B2 (en) 2024-12-24
CN109952376B (zh) 2023-09-05
EP3535397A4 (en) 2020-06-03
EA201991102A1 (ru) 2019-09-30
TW201829445A (zh) 2018-08-16
IL266343B2 (en) 2024-01-01
HRP20220181T1 (hr) 2022-04-29
JP2023105046A (ja) 2023-07-28

Similar Documents

Publication Publication Date Title
AU2017354041B2 (en) Alpha-V beta-6 integrin ligands and uses thereof
AU2002306500C1 (en) Transporters comprising spaced arginine moieties
CN103491982B (zh) 具有酶敏感性连接的多核苷酸体内递送偶联物
AU2018359515A1 (en) Integrin ligands and uses thereof
HK40014552B (en) Alpha-v beta-6 integrin ligands and uses thereof
BR112019008965B1 (pt) Ligante da integrina alfa-v beta-6 e composição compreendendo o mesmo
JP6966427B2 (ja) 生物学的に切断可能なテトラペプチド連結剤
CA2984499C (en) Biologically cleavable tetrapeptide linking agents
EA042923B1 (ru) Альфа-v бета-6 лиганды интегрина и варианты их применения
HK1188947A (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1188947B (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)